Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.

PubMed  Article  Google Scholar 

Organization WH. GLOBOCAN: International Agency for Research on Cancer. Section of cancer information. 2018.

Google Scholar 

Chatterjee J, Dai W, Abd Aziz NH, Teo PY, Wahba J, Phelps DL, et al. Clinical use of programmed cell death-1 and its ligand expression as discriminatory and predictive markers in ovarian cancer. Clin Cancer Res. 2017;23(13):3453–60.

CAS  PubMed  Article  Google Scholar 

Charbonneau B, Goode EL, Kalli KR, Knutson KL, DeRycke MS. The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol. 2013;33(2):137.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hartge P. Designing early detection programs for ovarian cancer. Oxford University Press. 2011;22(12 Suppl 8). https://doi.org/10.1093/annonc/mdr472.

Pujade-Lauraine E, Banerjee S, Pignata S. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives. J Clin Oncol. 2019;37(27):2437–48.

CAS  PubMed  Article  Google Scholar 

Hassan MK, Watari H, Christenson L, Bettuzzi S, Sakuragi N. Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel. Tumor Biol. 2011;32(5):1031–47.

CAS  Article  Google Scholar 

Shaik B, Zafar T, Balasubramanian K, Gupta SP. An overview of ovarian cancer: molecular processes involved and development of target-based chemotherapeutics. Curr Top Med Chem. 2021;21(4):329–46.

PubMed  Article  CAS  Google Scholar 

Karkhane M, Lashgarian HE, Hormozi M, Fallahi S, Cheraghipour K, Marzban A. Oncogenesis and tumor inhibition by microRNAs and its potential therapeutic applications: a systematic review. MicroRNA. 2020;9(3):198–215.

CAS  PubMed  Article  Google Scholar 

Shomali N, Shirafkan N, Duijf PHG, Ghasabi M, Babaloo Z, Yousefi M, et al. Downregulation of miR-146a promotes cell migration in Helicobacter pylori-negative gastric cancer. J Cell Biochem. 2019;120(6):9495–505.

CAS  PubMed  Article  Google Scholar 

Tamjidifar R, Akbari M, Tarzi S, Sadeghzadeh M, Abolghasemi M, Poursaei E, et al. Prognostic and diagnostic values of miR-506 and SPON 1 in colorectal cancer with clinicopathological considerations. J Gastrointest Cancer. 2021;52(1):125–9.

CAS  PubMed  Article  Google Scholar 

Hwang H, Mendell J. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006;94(6):776–80.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Nabipoorashrafi SA, Shomali N, Sadat-Hatamnezhad L, Mahami-Oskouei M, Mahmoudi J, Sandoghchian Shotorbani B, et al. miR-143 acts as an inhibitor of migration and proliferation as well as an inducer of apoptosis in melanoma cancer cells in vitro. IUBMB Life. 2020;72(9):2034–44.

CAS  PubMed  Article  Google Scholar 

Azar M, Aghazadeh H, Mohammed HN, Sara MRS, Hosseini A, Shomali N, et al. miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and oxaliplatin chemoresistance by targeting CXCR4. Int Immunopharmacol. 2021;92:107355.

CAS  PubMed  Article  Google Scholar 

Shomali N, Hatamnezhad LS, Tarzi S, Tamjidifar R, Xu H, Shotorbani SS. Heat shock proteins regulating toll-like receptors and the immune system could be a novel therapeutic target for melanoma. Curr Mol Med. 2021;21(1):15–24.

CAS  PubMed  Article  Google Scholar 

Srivastava SK, Ahmad A, Zubair H, Miree O, Singh S, Rocconi RP, et al. MicroRNAs in gynecological cancers: small molecules with big implications. Cancer Lett. 2017;407:123–38.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Yang H, Kong W, He L, Zhao J-J, O’Donnell JD, Wang J, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Can Res. 2008;68(2):425–33.

CAS  Article  Google Scholar 

Koutsaki M, Spandidos DA, Zaravinos A. Epithelial–mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics. Cancer Lett. 2014;351(2):173–81.

CAS  PubMed  Article  Google Scholar 

Krasniqi E, Sacconi A, Marinelli D, Pizzuti L, Mazzotta M, Sergi D, et al. MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study. Biomark Res. 2021;9(1):1–17.

Article  Google Scholar 

Krzystyniak J, Ceppi L, Dizon D, Birrer M. Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer. Ann Oncol. 2016;27:i4–10.

PubMed  PubMed Central  Article  Google Scholar 

Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609.

Article  CAS  Google Scholar 

Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. The Lancet. 2014;384(9951):1376–88.

Article  Google Scholar 

Zhao T, Shao Y, Liu Y, Wang X, Guan L, Lu Y. Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute. J Ovarian Res. 2018;11(1):1–10.

Article  CAS  Google Scholar 

Lalwani N, Prasad SR, Vikram R, Shanbhogue AK, Huettner PC, Fasih N. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Radiographics. 2011;31(3):625–46.

PubMed  Article  Google Scholar 

Xu W, Rush J, Rickett K, Coward JI. Mucinous ovarian cancer: a therapeutic review. Crit Rev Oncol Hematol. 2016;102:26–36.

PubMed  Article  Google Scholar 

Pietragalla A, Arcieri M, Marchetti C, Scambia G, Fagotti A. Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes. Int J Gynecol Cancer. 2020;30(11):1803.

PubMed  Article  Google Scholar 

Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol. 2016;2(11):1434–40.

PubMed  PubMed Central  Article  Google Scholar 

Shomali N, Marofi F, Tarzi S, Tamjdidfar R, Akbari M, Parvari S, et al. HSP90 inhibitor modulates HMGA1 and HMGB2 expression along with cell viability via NF-KB signaling pathways in melanoma in-vitro. Gene Reports. 2021;24:101205.

CAS  Article  Google Scholar 

Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–16.

CAS  PubMed  Article  Google Scholar 

Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, et al. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int. 2015;2015:341723. https://doi.org/10.1155/2015/341723.

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz F. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Centre for Reviews and Dissemination (UK): Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews; 2002.

Book  Google Scholar 

Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183–203.

PubMed  PubMed Central  Article  Google Scholar 

Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194–200.

CAS  PubMed  Article  Google Scholar 

Alvarez RD, Karlan BY, Strauss JF. “Ovarian cancers: evolving paradigms in research and care”: report from the institute of medicine. Gynecol Oncol. 2016;141(3):413–5.

PubMed  Article  Google Scholar 

Rustin GJ, Van Der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155–63.

PubMed  Article  Google Scholar 

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. Obstet Gynecol Surv. 2014;69(7):402–4.

Article  Google Scholar 

Chen H, Fang F, Liu GJ, Xie HY, Zou J, Feng D. Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst Rev. 2013;2013(6). https://doi.org/10.1002/14651858.CD007414.pub3.

Fletcher JI, Williams RT, Henderson MJ, Norris MD, Haber M. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist Updates. 2016;26:1–9.

Article  Google Scholar 

Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu H-Y, Lin L-T, et al. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol; 2015: Elsevier. 2015;35:S78–S103.

Pagotto A, Pilotto G, Mazzoldi EL, Nicoletto MO, Frezzini S, Pastò A, et al. Autophagy inhibition reduces chemoresistance and tumorigenic potential of human ovarian cancer stem cells. Cell Death Dis. 2017;8(7):e2943–e.

Article  CAS  Google Scholar 

Tomao F, Papa A, Rossi L, Strudel M, Vici P, Russo GL, et al. Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. J Exp Clin Cancer Res. 2013;32(1):1–14.

Article  Google Scholar 

Borley J, Brown R. Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer. Ann Med. 2015;47(5):359–69.

PubMed  Article  CAS  Google Scholar 

Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin a receptor pathway in ovarian carcinoma cells. Clin Cancer Res. 2011;17(8):2350–60.

PubMed